Siegmund A, Wolff D, Pagani A, Ruewe M, Klein S, Herr W
Ann Hematol. 2024; 103(11):4783-4787.
PMID: 39237815
PMC: 11534900.
DOI: 10.1007/s00277-024-05990-8.
Jiao H, Pang B, Liu A, Chen Q, Pan Q, Wang X
Nat Struct Mol Biol. 2024; 31(4):610-620.
PMID: 38177682
PMC: 11026165.
DOI: 10.1038/s41594-023-01175-5.
Jiao H, Pang B, Chiang Y, Chen Q, Pan Q, Ren R
Cell Discov. 2023; 9(1):119.
PMID: 38012179
PMC: 10682378.
DOI: 10.1038/s41421-023-00617-0.
Avni B, Neiman D, Shaked E, Gal-Rosenberg O, Grisariu S, Kuzli M
J Clin Invest. 2023; 134(2).
PMID: 37971879
PMC: 10786696.
DOI: 10.1172/JCI163541.
Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K
Cell Mol Immunol. 2023; 20(6):613-625.
PMID: 37165014
PMC: 10229573.
DOI: 10.1038/s41423-023-01022-z.
Cognitive impairments correlate with increased central nervous system immune activation after allogeneic haematopoietic stem cell transplantation.
Boberg E, Kadri N, Hagey D, Schwieler L, El Andaloussi S, Erhardt S
Leukemia. 2023; 37(4):888-900.
PMID: 36792657
PMC: 10079537.
DOI: 10.1038/s41375-023-01840-0.
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L, Liu Y, Wolff J, Yang L, Taing L, Jhaveri A
Blood. 2023; 141(15):1817-1830.
PMID: 36706355
PMC: 10122106.
DOI: 10.1182/blood.2022018246.
Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: A systematic review.
Milosevic E, Babic A, Iovino L, Markovic M, Grce M, Greinix H
Front Immunol. 2022; 13:1033263.
PMID: 36389657
PMC: 9641232.
DOI: 10.3389/fimmu.2022.1033263.
A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study.
Cuvelier G, Ng B, Abdossamadi S, Nemecek E, Melton A, Kitko C
Blood Adv. 2022; 7(14):3612-3623.
PMID: 36219586
PMC: 10365946.
DOI: 10.1182/bloodadvances.2022007715.
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.
Cuvelier G, Schoettler M, Buxbaum N, Pinal-Fernandez I, Schmalzing M, Distler J
Transplant Cell Ther. 2022; 28(8):426-445.
PMID: 35662591
PMC: 9557927.
DOI: 10.1016/j.jtct.2022.05.038.
RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea.
Zouali H, Lemasson J, Calugareanu A, Battail C, Michonneau D, Le Buanec H
Blood Adv. 2022; 6(9):2805-2811.
PMID: 35008096
PMC: 9092416.
DOI: 10.1182/bloodadvances.2021004707.
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer.
Zhou Q, Liang J, Yang T, Liu J, Li B, Li Y
EMBO Mol Med. 2021; 14(1):e14502.
PMID: 34898004
PMC: 8749493.
DOI: 10.15252/emmm.202114502.
C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease.
Magnusen A, Rani R, McKay M, Hatton S, Nyamajenjere T, Magnusen D
Int J Mol Sci. 2021; 22(23).
PMID: 34884512
PMC: 8657559.
DOI: 10.3390/ijms222312712.
Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease.
Orsatti L, Stiehl T, Dischinger K, Speziale R, Di Pasquale P, Monteagudo E
Cell Rep Med. 2021; 2(10):100409.
PMID: 34755129
PMC: 8561165.
DOI: 10.1016/j.xcrm.2021.100409.
LPS-Macrophages Alleviate the Outcome of Graft--Host Disease Without Aggravating Lymphoma Growth in Mice.
Jeljeli M, Chene C, Chouzenoux S, Thomas M, Segain B, Doridot L
Front Immunol. 2021; 12:670776.
PMID: 34413847
PMC: 8369416.
DOI: 10.3389/fimmu.2021.670776.
Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.
Shakshouk H, Tkaczyk E, Cowen E, El-Azhary R, Hashmi S, Kenderian S
Transplant Cell Ther. 2021; 27(9):738-746.
PMID: 34107339
PMC: 8719782.
DOI: 10.1016/j.jtct.2021.05.030.
EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion.
Chen Q, Jin J, Huang X, Wu F, Huang H, Zhan R
J Exp Clin Cancer Res. 2021; 40(1):160.
PMID: 33964937
PMC: 8106853.
DOI: 10.1186/s13046-021-01954-2.
Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.
Dai H, Rachakonda S, Penack O, Blau I, Blau O, Radujkovic A
Blood Cancer J. 2021; 11(2):42.
PMID: 33640906
PMC: 7914250.
DOI: 10.1038/s41408-021-00434-2.
[The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease].
Chen T, Li X, Zhang C, Kong P, Gao Q, Tang L
Zhonghua Xue Ye Xue Za Zhi. 2019; 40(11):948-952.
PMID: 31856446
PMC: 7342379.
DOI: 10.3760/cma.j.issn.0253-2727.2019.11.012.
Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.
Newell L, DeFor T, Cutler C, Verneris M, Blazar B, Miller J
Biol Blood Marrow Transplant. 2019; 26(3):606-611.
PMID: 31715306
PMC: 7219549.
DOI: 10.1016/j.bbmt.2019.11.006.